Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE3.2600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.0100/ 2
- Ask / Lots3.4200/ 4
- Open / Previous Close0.0000 / 3.2600
- Day Range---
- 52 Week Range
- Volume100
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KOD |
|---|---|---|
| 09:32 ET | 4478 | 3.19 |
| 09:34 ET | 11370 | 3.23 |
| 09:36 ET | 1716 | 3.2198 |
| 09:39 ET | 10019 | 3.24 |
| 09:41 ET | 1100 | 3.31 |
| 09:45 ET | 108 | 3.27 |
| 09:48 ET | 900 | 3.29 |
| 09:50 ET | 400 | 3.27 |
| 09:52 ET | 207 | 3.25 |
| 09:56 ET | 690 | 3.2363 |
| 09:57 ET | 2021 | 3.27 |
| 09:59 ET | 1000 | 3.2844 |
| 10:01 ET | 200 | 3.265 |
| 10:03 ET | 200 | 3.29 |
| 10:06 ET | 207 | 3.24 |
| 10:08 ET | 100 | 3.25 |
| 10:10 ET | 100 | 3.25 |
| 10:12 ET | 13170 | 3.28 |
| 10:14 ET | 17207 | 3.28 |
| 10:15 ET | 5866 | 3.2872 |
| 10:17 ET | 300 | 3.29 |
| 10:19 ET | 819 | 3.28 |
| 10:21 ET | 13400 | 3.3 |
| 10:24 ET | 800 | 3.31 |
| 10:26 ET | 400 | 3.31 |
| 10:28 ET | 42053 | 3.32 |
| 10:30 ET | 15043 | 3.31 |
| 10:32 ET | 21174 | 3.33 |
| 10:33 ET | 100 | 3.34 |
| 10:35 ET | 18936 | 3.33 |
| 10:37 ET | 200 | 3.33 |
| 10:42 ET | 1007 | 3.35 |
| 10:44 ET | 600 | 3.35 |
| 10:46 ET | 1300 | 3.37 |
| 10:48 ET | 6112 | 3.35 |
| 10:50 ET | 1002 | 3.36 |
| 10:51 ET | 7800 | 3.34 |
| 10:53 ET | 2329 | 3.35 |
| 10:55 ET | 9400 | 3.3595 |
| 10:57 ET | 100 | 3.36 |
| 11:00 ET | 300 | 3.36 |
| 11:02 ET | 3900 | 3.37 |
| 11:04 ET | 993 | 3.3725 |
| 11:06 ET | 13500 | 3.375 |
| 11:08 ET | 4346 | 3.3801 |
| 11:09 ET | 200 | 3.3707 |
| 11:11 ET | 2797 | 3.3701 |
| 11:13 ET | 637 | 3.36 |
| 11:15 ET | 8343 | 3.33 |
| 11:18 ET | 100 | 3.315 |
| 11:20 ET | 700 | 3.3075 |
| 11:22 ET | 107 | 3.31 |
| 11:24 ET | 400 | 3.3 |
| 11:26 ET | 207 | 3.285 |
| 11:27 ET | 100 | 3.285 |
| 11:31 ET | 207 | 3.2775 |
| 11:33 ET | 2600 | 3.286 |
| 11:36 ET | 108 | 3.28 |
| 11:38 ET | 100 | 3.285 |
| 11:40 ET | 2900 | 3.285 |
| 11:42 ET | 10300 | 3.2701 |
| 11:44 ET | 1100 | 3.2725 |
| 11:45 ET | 108 | 3.265 |
| 11:47 ET | 100 | 3.2625 |
| 11:49 ET | 100 | 3.2625 |
| 11:51 ET | 608 | 3.2525 |
| 11:54 ET | 200 | 3.2501 |
| 11:56 ET | 300 | 3.2414 |
| 11:58 ET | 100 | 3.2425 |
| 12:02 ET | 200 | 3.24 |
| 12:03 ET | 100 | 3.225 |
| 12:07 ET | 100 | 3.225 |
| 12:09 ET | 300 | 3.225 |
| 12:14 ET | 1087 | 3.26 |
| 12:20 ET | 200 | 3.2507 |
| 12:25 ET | 100 | 3.26 |
| 12:38 ET | 100 | 3.255 |
| 12:48 ET | 200 | 3.27 |
| 12:52 ET | 100 | 3.27 |
| 12:54 ET | 100 | 3.27 |
| 12:56 ET | 100 | 3.26 |
| 12:57 ET | 100 | 3.26 |
| 01:01 ET | 100 | 3.27 |
| 01:03 ET | 100 | 3.29 |
| 01:06 ET | 100 | 3.29 |
| 01:08 ET | 100 | 3.29 |
| 01:12 ET | 100 | 3.29 |
| 01:14 ET | 100 | 3.29 |
| 01:17 ET | 26233 | 3.29 |
| 01:19 ET | 100 | 3.29 |
| 01:21 ET | 300 | 3.29 |
| 01:24 ET | 300 | 3.29 |
| 01:26 ET | 4750 | 3.3 |
| 01:28 ET | 69195 | 3.3 |
| 01:30 ET | 949 | 3.32 |
| 01:33 ET | 337 | 3.34 |
| 01:35 ET | 900 | 3.34 |
| 01:37 ET | 200 | 3.34 |
| 01:42 ET | 21925 | 3.3316 |
| 01:44 ET | 455 | 3.345 |
| 01:46 ET | 200 | 3.35 |
| 01:48 ET | 100 | 3.35 |
| 01:51 ET | 200 | 3.36 |
| 01:53 ET | 100 | 3.34 |
| 01:55 ET | 485 | 3.35 |
| 02:00 ET | 8200 | 3.355 |
| 02:02 ET | 200 | 3.35 |
| 02:04 ET | 2900 | 3.305 |
| 02:06 ET | 600 | 3.31 |
| 02:11 ET | 245 | 3.33 |
| 02:13 ET | 27000 | 3.32 |
| 02:15 ET | 200 | 3.33 |
| 02:24 ET | 1598 | 3.3 |
| 02:26 ET | 100 | 3.3 |
| 02:29 ET | 1321 | 3.29 |
| 02:31 ET | 300 | 3.28 |
| 02:33 ET | 100 | 3.28 |
| 02:38 ET | 838 | 3.28 |
| 02:42 ET | 400 | 3.28 |
| 02:44 ET | 100 | 3.28 |
| 02:45 ET | 300 | 3.28 |
| 02:49 ET | 100 | 3.28 |
| 02:51 ET | 100 | 3.28 |
| 02:54 ET | 1694 | 3.28 |
| 02:58 ET | 200 | 3.25 |
| 03:02 ET | 300 | 3.27 |
| 03:03 ET | 800 | 3.27 |
| 03:05 ET | 1500 | 3.3 |
| 03:07 ET | 1100 | 3.29 |
| 03:09 ET | 24600 | 3.305 |
| 03:12 ET | 6330 | 3.28 |
| 03:16 ET | 355 | 3.2835 |
| 03:18 ET | 100 | 3.29 |
| 03:20 ET | 1317 | 3.26 |
| 03:21 ET | 597 | 3.26 |
| 03:23 ET | 202 | 3.255 |
| 03:25 ET | 100 | 3.255 |
| 03:27 ET | 200 | 3.255 |
| 03:30 ET | 525 | 3.25 |
| 03:32 ET | 1200 | 3.26 |
| 03:38 ET | 100 | 3.26 |
| 03:41 ET | 200 | 3.26 |
| 03:43 ET | 500 | 3.255 |
| 03:45 ET | 200 | 3.25 |
| 03:48 ET | 20440 | 3.258 |
| 03:50 ET | 1999 | 3.26 |
| 03:52 ET | 500 | 3.26 |
| 03:54 ET | 700 | 3.25 |
| 03:56 ET | 1500 | 3.26 |
| 03:57 ET | 800 | 3.25 |
| 03:59 ET | 1345 | 3.26 |
May 15, 2024
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones*DJ Kodiak Sciences 1Q Loss/Shr 82c >KOD, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones
May 13, 2024
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy, from 7:32PM ET on Monday May 13, 2024 by Dow Jones
7:32PM ET on Monday May 13, 2024 by Dow Jones
May 2, 2024
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform, from 4:30PM ET on Thursday May 02, 2024 by Dow Jones
4:30PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 171.3M | -0.7x | --- |
Greenwich Lifesciences Inc | 173.9M | -19.5x | --- |
Achieve Life Sciences Inc | 176.9M | -4.0x | --- |
RAPT Therapeutics Inc | 161.1M | -1.5x | --- |
Outlook Therapeutics Inc | 186.4M | -0.7x | --- |
Trevi Therapeutics Inc | 186.7M | -7.8x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $171.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.42 |
EPS | $-4.44 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
